These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34120773)

  • 1. A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Gong X; Li L; Wei H; Liu B; Zhou C; Zhang G; Liu K; Lin D; Gong B; Wei S; Li Y; Mi Y; Wang Y; Wang J
    Clin Ther; 2021 Jul; 43(7):1265-1271.e1. PubMed ID: 34120773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Shen S; Chen X; Cai J; Yu J; Gao J; Hu S; Zhai X; Liang C; Ju X; Jiang H; Jin R; Wu X; Wang N; Tian X; Pan K; Jiang H; Sun L; Fang Y; Li CK; Hu Q; Yang M; Zhu Y; Zhang H; Li C; Pei D; Jeha S; Yang JJ; Cheng C; Tang J; Zhu X; Pui CH
    JAMA Oncol; 2020 Mar; 6(3):358-366. PubMed ID: 31944221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
    Porkka K; Koskenvesa P; Lundán T; Rimpiläinen J; Mustjoki S; Smykla R; Wild R; Luo R; Arnan M; Brethon B; Eccersley L; Hjorth-Hansen H; Höglund M; Klamova H; Knutsen H; Parikh S; Raffoux E; Gruber F; Brito-Babapulle F; Dombret H; Duarte RF; Elonen E; Paquette R; Zwaan CM; Lee FY
    Blood; 2008 Aug; 112(4):1005-12. PubMed ID: 18477770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
    Mustafa Ali MK; Sabha MM; Al-Rabi KH
    Platelets; 2015; 26(5):491-4. PubMed ID: 25025538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
    Wong SF
    J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Piccaluga PP; Paolini S; Martinelli G
    Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
    Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center].
    Zhang GJ; Gong XY; Qiu SW; Zhou CL; Liu KQ; Lin D; Liu BC; Wei H; Wei SN; Li Y; Gu RX; Gong BF; Liu YT; Fang QY; Mi YC; Wang Y; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):109-115. PubMed ID: 33858040
    [No Abstract]   [Full Text] [Related]  

  • 12. Philadelphia chromosome-positive acute lymphoblastic leukemia with extramedullary and meningeal relapse after allogeneic hematopoietic stem cell transplantation that was successfully treated with dasatinib.
    Kondo T; Tasaka T; Matsumoto K; Matsumoto R; Koresawa L; Sano F; Tokunaga H; Matsuhashi Y; Nakanishi H; Morita K; Wada H; Sugihara T
    Springerplus; 2014; 3():177. PubMed ID: 24790822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.
    Ravandi F
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):198-203. PubMed ID: 21575924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of ovarian stimulation for fertility preservation in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after treatment with dasatinib.
    Ogawa T; Ogi M; Hirata S
    J Obstet Gynaecol Res; 2021 Mar; 47(3):1182-1185. PubMed ID: 33469980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Keam SJ
    BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
    Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hagihara M; Hua J; Inoue M; Uchida T; Ide S; Ohara S; Takaku T
    Int J Hematol; 2020 May; 111(5):719-723. PubMed ID: 31894532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
    Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
    Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.